# Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)

> **NCT05142514** · PHASE2 · COMPLETED · sponsor: **Hipra Scientific, S.L.U** · enrollment: 629 (actual)

## Conditions studied

- COVID-19
- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccine HIPRA
- **BIOLOGICAL:** Cominarty (Pfizer-BioNtech)

## Key facts

- **NCT ID:** NCT05142514
- **Lead sponsor:** Hipra Scientific, S.L.U
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-11
- **Primary completion:** 2021-12-27
- **Final completion:** 2022-05-06
- **Target enrollment:** 629 (ACTUAL)
- **Last updated:** 2024-02-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142514, "Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT05142514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*